Search Results - "Neill, Jo C"

Refine Results
  1. 1

    A systematic review and meta-analysis of cognitive remediation in early schizophrenia by Revell, Emily R, Neill, Jo C, Harte, Michael, Khan, Zarshed, Drake, Richard J

    Published in Schizophrenia research (01-10-2015)
    “…Abstract Neurocognitive impairment predicts disability in schizophrenia, making intervention theoretically attractive as a means to minimise chronic…”
    Get full text
    Journal Article
  2. 2

    Nicotinic α7 and α4β2 agonists enhance the formation and retrieval of recognition memory: Potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders by McLean, Samantha L., Grayson, Ben, Marsh, Samuel, Zarroug, Samah H.O., Harte, Michael K., Neill, Jo C.

    Published in Behavioural brain research (01-04-2016)
    “…•Object recognition memory decays to 0 after a 6h ITI in female hL rats.•Activation of nicotinic α7 and α4b2 receptors restores this memory.•Donepezil restores…”
    Get full text
    Journal Article
  3. 3

    Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia by McLean, Samantha L, Grayson, Ben, Idris, Nagi F, Lesage, Anne S, Pemberton, Darrel J, Mackie, Claire, Neill, Jo C

    Published in European neuropsychopharmacology (01-04-2011)
    “…Abstract Rationale Nicotinic α7 acetylcholine receptors (nAChRs) have been highlighted as a target for cognitive enhancement in schizophrenia. Aim To…”
    Get full text
    Journal Article
  4. 4

    Adverse effects of psychedelics: From anecdotes and misinformation to systematic science by Schlag, Anne K, Aday, Jacob, Salam, Iram, Neill, Jo C, Nutt, David J

    Published in Journal of Psychopharmacology (01-03-2022)
    “…Background: Despite an increasing body of research highlighting their efficacy to treat a broad range of medical conditions, psychedelic drugs remain a…”
    Get full text
    Book Review Journal Article
  5. 5

    Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats by Damgaard, Trine, Larsen, Dorrit Bjerg, Hansen, Suzanne L., Grayson, Ben, Neill, Jo C., Plath, Niels

    Published in Behavioural brain research (11-02-2010)
    “…Cognitive deficits are a major clinical unmet need in schizophrenia. The psychotomimetic drug phencyclidine (PCP) is widely applied in rodents to mimic…”
    Get full text
    Journal Article
  6. 6

    Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat by McLean, Samantha L., Neill, Jo C., Idris, Nagi F., Marston, Hugh M., Wong, Erik H.F., Shahid, Mohammed

    Published in Behavioural brain research (25-12-2010)
    “…Asenapine is a new pharmacological agent for the acute treatment of schizophrenia and bipolar disorder. It has relatively higher affinity for serotonergic and…”
    Get full text
    Journal Article
  7. 7

    D1 receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test by Barnes, Samuel A., Young, Jared W., Neill, Jo C.

    Published in Psychopharmacologia (01-03-2012)
    “…Rationale Impaired attention/vigilance is putatively core to schizophrenia. The dopaminergic D 1 receptor system has been reported as one of the most promising…”
    Get full text
    Journal Article
  8. 8

    Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology by Neill, Jo C, Grayson, Ben, Kiss, Béla, Gyertyán, István, Ferguson, Paul, Adham, Nika

    Published in European neuropsychopharmacology (01-01-2016)
    “…Abstract Negative symptoms and cognitive impairment associated with schizophrenia are strongly associated with poor functional outcome and reduced quality of…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11

    Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism by Snigdha, Shikha, Idris, Nagi, Grayson, Ben, Shahid, Mohammed, Neill, Jo C.

    Published in Psychopharmacologia (01-04-2011)
    “…Rationale Cognitive deficits are common in schizophrenia. Asenapine is an atypical antipsychotic approved by the US Food and Drug Administration in adults for…”
    Get full text
    Journal Article
  12. 12

    Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia by Damgaard, Trine, Plath, Niels, Neill, Jo C., Hansen, Suzanne L.

    Published in Psychopharmacologia (01-03-2011)
    “…Rationale Schizophrenia is a complex psychiatric disorder comprised of three main classes of symptoms: positive, negative and cognitive symptoms. Currently, no…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Rats tested after a washout period from sub-chronic PCP administration exhibited impaired performance in the 5-Choice Continuous Performance Test (5C-CPT) when the attentional load was increased by Barnes, Sam A., Young, Jared W., Neill, Jo C.

    Published in Neuropharmacology (01-03-2012)
    “…It is well documented that schizophrenia patients exhibit dysfunction in various cognitive domains, including attention/vigilance, as demonstrated by impaired…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania by Tarazi, Frank I, Neill, Jo C

    Published in Expert opinion on drug discovery (01-01-2013)
    “…Asenapine is a novel antipsychotic drug approved for the treatment of acute schizophrenia, manic, or mixed episodes associated with bipolar I disorder, as a…”
    Get more information
    Journal Article
  18. 18

    Activation of alpha 7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia by McLean, Samantha L, Grayson, Ben, Idris, Nagi F, Lesage, Anne S, Pemberton, Darrel J, Mackie, Claire, Neill, Jo C

    Published in European neuropsychopharmacology (01-04-2011)
    “…Nicotinic alpha 7 acetylcholine receptors (nAChRs) have been highlighted as a target for cognitive enhancement in schizophrenia. Aim: To investigate whether…”
    Get full text
    Journal Article
  19. 19

    Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia by Barnes, Samuel A, Sawiak, Stephen J, Caprioli, Daniele, Jupp, Bianca, Buonincontri, Guido, Mar, Adam C, Harte, Michael K, Fletcher, Paul C, Robbins, Trevor W, Neill, Jo C, Dalley, Jeffrey W

    “…N-methyl-d-aspartate receptor (NMDAR) dysfunction is thought to contribute to the pathophysiology of schizophrenia. Accordingly, NMDAR antagonists such as…”
    Get full text
    Journal Article
  20. 20

    First episode psychosis patients show impaired cognitive function – a study of a South Asian population in the UK by Saleem, Majid M, Harte, Michael K, Marshall, Kay M, Scally, Andy, Brewin, Anita, Neill, Jo C

    Published in Journal of psychopharmacology (Oxford) (01-04-2013)
    “…Background: Cognitive deficits are a core symptom of schizophrenia, severely debilitating and untreated by current medication. However, to date there is…”
    Get full text
    Journal Article